BB Biotech AG : Update portefeuille poste T2 2021: OC relevé à 82 €
>Momentum positif maintenu au T2 - BB Biotech a publié vendredi dernier ses résultats du T2 2021. La tendance positive du résultat enregistrée en début d’année s’est maintenue au T2 faisant écho à la reprise sectorielle enregistrée sur la période (NBI en progression de 8% vs -0.5% au T1) avec une progression du cours de 5.8% en CHF et 6.1% en €. Le portefeuille a progressé de 3.3%, de 4.2% et 5.3% respectivement en CHF, € et $ résultant en un gain net de 128 MCHF (vs ...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.